Roche warns counterfeit Avastin now in US market
Phil Taylor, 15-Feb-2012
Roche subsidiary Genentech
has said that counterfeit copies of its big-selling cancer drug
Avastin which do not contain any active ingredient have been
encountered in the US market.
Avastin (bevacizumab) has already been targeted by counterfeiters
in China, with fake versions used off-label at a Chinese hospital
specialising in eye disorders, leading to complications in dozens
of patients (see NEJM
publishes counterfeit bevacizumab details).
Now, illegal copies of the drug in 400mg/16mL vials have been
identified as being distributed in the USA, where the drug is
approved to treat various cancers, including those affecting the
colon, lung, kidney and brain. Genentech has confirmed in
laboratory testing that the copies are counterfeit and contain no
active ingredient, placing patients at risk of treatment
failure.
A Food and Drug Administration (FDA) notice advises that the
counterfeit versions are in Roche rather than Genentech livery
(Roche manufactures the drug outside the US) and display batch
numbers that start with B6010, B6011 or B86017.
"The FDA-approved version does not include the Roche logo on the
packaging or vials," said the agency in a statement.
At least 19 medical practices are thought to have purchased the
fraudulent product from Quality Special Products, an overseas
supplier that is also thought to operate as Montana Health Care
Solutions.
Volunteer Distribution in Gainesboro, Tennessee, is a distributor
of QSP's products, according to the FDA. According to Genentech,
none of the suppliers mentioned by the FDA are authorised to
distribute Avastin.
Interestingly, in India Roche has taken specific measures to help
protect Avastin from counterfeiting and has seen good results in
recent years. The company makes use of a system developed by
Norwegian company Kezzler in India which allows patients to
authenticate their own medicines by texting a 16-digit serial
number printed on the pack to a central SMS number.
Roche implemented Kezzler's system five years and has not
encountered any counterfeit Avastin in the Indian market in the
last three years, according to a Kezzler spokesman.
©
SecuringIndustry.com